Barclays PLC Purchases 20,777 Shares of Agenus Inc. (NASDAQ:AGEN)

Barclays PLC boosted its stake in Agenus Inc. (NASDAQ:AGEN) by 295.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,813 shares of the biotechnology company’s stock after purchasing an additional 20,777 shares during the quarter. Barclays PLC owned about 0.12% of Agenus worth $152,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently made changes to their positions in AGEN. Walleye Capital LLC bought a new stake in shares of Agenus in the 3rd quarter worth approximately $1,003,000. Federated Hermes Inc. bought a new stake in shares of Agenus during the second quarter valued at approximately $1,921,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Agenus in the 2nd quarter worth about $1,050,000. BNP Paribas Financial Markets lifted its holdings in shares of Agenus by 2,271.5% during the third quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 37,866 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new position in Agenus during the second quarter valued at $614,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Stock Performance

Shares of NASDAQ:AGEN opened at $3.55 on Wednesday. The stock has a market capitalization of $83.28 million, a price-to-earnings ratio of -0.32 and a beta of 1.27. The stock’s 50-day simple moving average is $3.25 and its two-hundred day simple moving average is $5.87. Agenus Inc. has a 52-week low of $2.50 and a 52-week high of $19.69.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating on shares of Agenus in a research note on Thursday, December 5th. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.